Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec®, Gleevec™)

Medizinische Klinik

Volumn 97, Issue SUPPL. 1, 2002, Pages 28-30

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

GIST; Imatinib; Inoperable gastrointestinal stromal tumors; Therapy; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB;

CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; GASTROINTESTINAL TUMOR; HUMAN; INOPERABLE CANCER; PHILADELPHIA 1 CHROMOSOME; SHORT SURVEY; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SARCOMA; STROMAL CELLS; TREATMENT OUTCOME;

EID: 0037080402     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (29)

1. Aberant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential
2. Abl protein-tyrosine kinase inhibitor STI 571 inhibits
3. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia
4. The proto oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus
5. C-kit immunocytochemical staining in the cytologic diagnosis of metastatic gastrointestinal stromal tumor
6. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias
7. Two hundred gastrointestinal stromal rumors. Recurrence patterns and prognostic factors for survival
8. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
9. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in Chronic myeloid leukemia
10. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
11. Modelling study of protein kinase inhibitors: Binding mode of starosporine and origin of the selectivity of CGD 5241
12. The dominant white spotting (W) locus of the mouse encodes the c-kit proto-oncogene
13. Detection and qualification of residual disease in chronic mylogenous leukemia
14. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor
15. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
16. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
17. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors
18. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
19. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
20. Biological and clinical review of stromal tumors in the gastrointestinal tract
21. A minute chromosome in human chronic granulocytic leukemia
22. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia
23. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management
24. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: Differences in clinical outcome and expression of multidrug resistance proteins
25. Primary structure of c-kit: Relationship with the CSF-1/PDFG receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C-terminus
26. Protein tyrosine kinase inhibitors in cancer treatment
27. Human protooncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand